CD274 and triple-negative breast carcinoma: Although some triple-negative breast cancer (TNBC) patients have high PD-L1 expression, they are accompanied by high immunosuppression in clinical trials with PD-1 or PD-L1 blockade, as reflected by low levels of T-cell infiltration and low clinical response rates7–9.